SU5614

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 D8351
SU5614	Acute Myeloid Leukemia

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

FLT3 G697R1
K 252a + Midostaurin + SU5614Substitutes	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Resistance	3	submitted	EID7604 Constructs of Ba/F3 cell line containing the FLT3 open reading frame with an internal tandem duplication of (FLT3-ITD) were used to induce point mutations in the ATP binding pocket of FLT3. Constructs… (full text at CIViC) PMID 15374944 · Cools et al., 2004 · Open in CIViC	civic

FLT3 ITD1
SU5614	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID131 Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutati… (full text at CIViC) PMID 15626738 · Bagrintseva et al., 2005 · Open in CIViC	civic